Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin. nov, vol.68, issue.6, pp.394-424, 2018. ,
1st International consensus guidelines for advanced breast cancer (ABC 1), Breast Edinb Scotl. juin, vol.21, issue.3, pp.242-52, 2012. ,
Projection de l'incidence et de la mortalité en France métropolitaine en, 2017. ,
Estimation de l'incidence départementale des cancers en France métropolitaine, 2008. ,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012 -Partie 1 -Tumeurs solides ,
Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 / Partie 1 -Tumeurs solides -7 ,
Chapitre1 -Épidémiologie des cancers du sein, Cancer du Sein, pp.5-10, 2016. ,
Prise en charge initiale du cancer épithélial de l'ovaire. Introduction aux Recommandations de pratiques cliniques françaises communes de FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisées par l'INCa, Gynécologie Obstétrique Fertil Sénologie. 1 févr, vol.47, issue.2, pp.93-97, 2019. ,
Ovarian cancer: epidemiology and risk factors, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.26, issue.1, pp.55-62, 2017. ,
Cancer du sein : risque génétique. Imagerie de la femme, 2016. ,
Inherited Mutations in Women With Ovarian Carcinoma, JAMA Oncol. avr, vol.2, issue.4, pp.482-90, 2016. ,
Les formes héréditaires des cancers de l'ovaire, Bull Cancer (Paris). 1 avr, vol.99, issue.4, pp.453-62, 2012. ,
Institut national du cancer. Cancer du sein -Quelles modalités de dépistage, Pathol Biol, vol.54, issue.4, pp.230-50, 2006. ,
Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage, 2014. ,
Estimation du risque individuel de cancer du sein : intérêt et limites des modèles de calcul de risque, Imag Femme. 1 juin, vol.24, issue.2, pp.97-104, 2014. ,
, Oncogénétique en 2017 /consultations et laboratoires, INCa, 2019.
Chapitre2 -Prédisposition génétique au cancer du sein, Cancer du Sein ,
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer, Annu Rev Cancer Biol. mars, vol.2, pp.313-349, 2018. ,
,
, Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med. 4 juin, vol.372, issue.23, pp.2243-57, 2015.
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, JAMA, vol.20, issue.23, pp.2402-2418, 2017. ,
Germline RAD51C mutations confer susceptibility to ovarian cancer, Nat Genet. avr, vol.44, issue.5, pp.475-481, 2012. ,
Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet. août, vol.43, issue.9, pp.879-82, 2011. ,
Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes, Eur J Hum Genet EJHG, vol.22, issue.11, pp.1305-1318, 2014. ,
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families, J Med Genet. janv, vol.53, issue.1, pp.34-42, 2016. ,
,
, Recommandations françaises du Groupe Génétique et Cancer pour l'analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l'ovaire. Bull Cancer (Paris), vol.105, pp.907-924, 2018.
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, vol.29, issue.11, pp.1282-91, 2008. ,
Screening for familial cancer risk: Focus on breast cancer. Maturitas, vol.105, pp.69-77, 2017. ,
New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, vol.302, issue.5645, pp.643-649, 2003. ,
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer, Cancer. 15 mai, vol.115, issue.10, pp.2222-2255, 2009. ,
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet. mai, vol.72, issue.5, pp.1117-1147, 2003. ,
Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.25, issue.11, pp.1329-1362, 2007. ,
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst. 5 juin, vol.105, issue.11, pp.812-834, 2013. ,
Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer, Semin Surg Oncol. juin, vol.18, issue.4, pp.287-95, 2000. ,
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.20, issue.9, pp.2310-2318, 2002. ,
Pathology of hereditary breast cancer, Mod Pathol Off J U S Can Acad Pathol Inc. mai, vol.23, issue.2, pp.46-51, 2010. ,
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers, Clin Cancer Res Off J Am Assoc Cancer Res. 1 avr, vol.10, issue.7, pp.2473-81, 2004. ,
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers, J Clin Oncol Off J Am Soc Clin Oncol. 10 févr, vol.119, issue.1, pp.409-427, 2010. ,
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, Br J Cancer. 26 avr, vol.104, issue.9, pp.1384-92, 2011. ,
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst. 5 déc, vol.99, issue.23, pp.1811-1815, 2007. ,
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Fam Cancer. juin, vol.11, issue.2, pp.235-277, 2012. ,
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore), vol.95, p.4975, 2016. ,
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer, Curr Treat Options Oncol. 15 nov, vol.19, issue.12, p.1, 2018. ,
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial, Lancet Oncol. janv, vol.16, issue.1, pp.87-97, 2015. ,
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N Engl J Med, vol.01, issue.22, pp.2154-64, 2016. ,
, Institut national du cancer. Femmes porteuses d'une mutation de BRCA1 ou de BRCA2
, Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque
,
, BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study, J Clin Oncol Off J Am Soc Clin Oncol. 20 déc, vol.28, issue.36, pp.5265-73, 2010.
The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations, J Womens Health, vol.18, issue.7, pp.1019-1043, 2002. ,
Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.33, issue.10, pp.1128-1163, 2015. ,
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis, Br J Cancer. 15 mars, vol.114, issue.6, pp.631-638, 2016. ,
Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition, Breast Cancer Res Treat. janv, vol.119, issue.2, pp.399-407, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00535408
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.29, issue.13, pp.1664-1673, 2011. ,
,
, Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging, Clin Breast Cancer. avr, vol.10, issue.2, pp.113-121, 2010.
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results, Invest Radiol. févr, vol.46, issue.2, pp.94-105, 2011. ,
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study, Breast Cancer Res Treat. avr, vol.144, issue.3, pp.577-82, 2014. ,
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK), BMJ. 6 sept, vol.345, p.5660, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-02282766
DNA double-strand breaks induced by mammographic screening procedures in human mammary epithelial cells, Int J Radiat Biol, vol.87, issue.11, pp.1103-1115, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00640764
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations, Br J Cancer. 26 juin, vol.107, issue.1, pp.24-30, 2012. ,
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?, Int J Cancer. 15 févr, vol.124, issue.4, pp.919-942, 2009. ,
Surveillance of women at high risk for hereditary ovarian cancer is inefficient, Br J Cancer. 27 mars, vol.94, issue.6, pp.814-823, 2006. ,
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers, Breast Cancer Res Treat. 13 juill, 2019. ,
Application of screening principles to the reconstructed breast, J Clin Oncol Off J Am Soc Clin Oncol. 1 janv, vol.28, issue.1, pp.173-80, 2010. ,
Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers, Breast Edinb Scotl. févr, 2014. ,
Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study, Eur J Cancer Oxf Engl, vol.48, issue.9, pp.1263-1271, 1990. ,
Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery, Breast Edinb Scotl. déc, vol.19, issue.6, pp.462-471, 2010. ,
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health. 12 déc, vol.14, p.150, 2014. ,
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA. 1 sept, vol.304, issue.9, pp.967-75, 2010. ,
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst. 21 janv, vol.101, issue.2, pp.80-87, 2009. ,
,
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst. mai, vol.107, issue.5, 2015. ,
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene, Clin Genet. mars, vol.75, issue.3, pp.220-224, 2009. ,
The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation, Psychooncology. janv, vol.22, issue.1, pp.212-221, 2013. ,
Contemporary Hormonal Contraception and the Risk of Breast Cancer, N Engl J Med, vol.07, issue.23, pp.2228-2267, 2017. ,
Oral contraceptive use and breast cancer: a prospective study of young women, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.19, issue.10, pp.2496-502, 2010. ,
Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.11, issue.11, pp.1375-81, 2002. ,
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis, Eur J Cancer Oxf Engl, vol.46, issue.12, pp.2275-84, 1990. ,
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis, Expert Rev Anticancer Ther. août, vol.11, issue.8, pp.1197-207, 2011. ,
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.33, pp.4188-98, 2013. ,
IVF and breast cancer: a systematic review and meta-analysis, Hum Reprod Update. févr, vol.20, issue.1, pp.106-129, 2014. ,
Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of populationbased studies, Breast Cancer Res Treat. avr, vol.150, issue.2, pp.405-418, 2015. ,
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study, Breast Cancer Res Treat, vol.167, issue.3, pp.761-770, 2018. ,
,
, Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study, Cancer Causes Control CCC. déc, vol.19, issue.10, pp.1111-1120, 2008.
Ovulationstimulation drugs and cancer risks: a long-term follow-up of a British cohort, Br J Cancer. 2 juin, vol.100, issue.11, pp.1824-1855, 2009. ,
Ovarian tumors in a cohort of infertile women, N Engl J Med. 22 sept, vol.331, issue.12, pp.771-777, 1994. ,
,
, Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis, Hum Reprod Update. avr, vol.19, issue.2, pp.105-128, 2013.
Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers, Fertil Steril. mai, vol.103, issue.5, pp.1305-1317, 2015. ,
Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: literature review, J Gynecol Obstet Biol Reprod, vol.44, issue.1, pp.10-17, 2015. ,
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations, JNCI Cancer Spectr. déc, vol.2, issue.4, p.78, 2018. ,
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation, Oncotarget. 7 févr, vol.8, issue.6, pp.9144-54, 2017. ,
,
, Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, Breast Cancer Res BCR. 9 mars, vol.14, issue.2, p.42, 2012.
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations, Am J Epidemiol, vol.160, issue.7, pp.613-621, 2004. ,
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation, Breast Cancer Res Treat, vol.142, issue.1, pp.177-85, 2013. ,
Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control CCC, vol.13, pp.299-305, 2002. ,
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA. 17 juill, vol.288, issue.3, pp.321-354, 2002. ,
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Res Treat. juin, vol.145, issue.2, pp.535-578, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01319982
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a casecontrol study, Breast Cancer Res Treat. janv, vol.155, issue.2, pp.365-73, 2016. ,
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers, JAMA Oncol. 1 août, vol.4, issue.8, pp.1059-65, 2018. ,
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.31, pp.7804-7814, 2005. ,
Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis, Menopause N Y N. avr, vol.13, issue.2, pp.265-79, 2006. ,
Increased cardiovascular mortality after early bilateral oophorectomy, Menopause N Y N. févr, vol.16, issue.1, pp.15-23, 2009. ,
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer, Gynecol Oncol. avr, vol.113, issue.1, pp.128-161, 2009. ,
Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers, Gynecol Oncol. août, vol.122, issue.2, pp.339-382, 2011. ,
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy, Fam Cancer. mars, vol.11, issue.1, pp.69-75, 2012. ,
Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT, Br J Cancer. 28 juin, vol.105, issue.1, pp.22-29, 2011. ,
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause, Neurology. 11 sept, vol.69, issue.11, pp.1074-83, 2007. ,
Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers, Clin Breast Cancer. 26 juill, 2018. ,
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation, Gynecol Oncol. avr, vol.121, issue.1, pp.163-171, 2011. ,
Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study, Eur J Cancer Oxf Engl, vol.84, pp.159-67, 1990. ,
Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy, Menopause N Y N. 16 juill, 2018. ,
Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 15 juin, 2019. ,
Anxiety and specific distress in women at intermediate and high risk of breast cancer before and after surveillance by magnetic resonance imaging and mammography versus standard mammography, Psychooncology, vol.21, issue.11, pp.1185-94, 2012. ,
Breast cancer screening: On our way to the future, Bull Cancer, vol.103, issue.9, pp.753-63, 2016. ,
Detection of cancer DNA in plasma of patients with early-stage breast cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 15 mai, vol.20, issue.10, pp.2643-50, 2014. ,
An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data, J Genet Couns. avr, vol.27, issue.2, pp.446-56, 2018. ,
« Primary peritoneal » high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer, Gynecol Oncol. mars, vol.120, issue.3, pp.470-473, 2011. ,
Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development, Gynecol Oncol. 1 juin, vol.121, issue.3, pp.472-478, 2011. ,
Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?, Bull Cancer, vol.103, issue.3, pp.273-81, 2016. ,
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data, Lancet Lond Engl. 25 mai, vol.381, issue.9880, pp.1827-1861, 2013. ,
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med. 16 avr, vol.158, issue.8, pp.604-618, 2013. ,
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials, J Natl Cancer Inst. févr, vol.108, issue.2, 2016. ,
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, doubleblind, randomised placebo-controlled trial, Lancet Lond Engl. 22 mars, vol.383, issue.9922, pp.1041-1049, 2014. ,
Exemestane for breast-cancer prevention in postmenopausal women, N Engl J Med. 23 juin, vol.364, issue.25, pp.2381-91, 2011. ,
, Diagnostic prénatal, interruption médicale de grossesse, diagnostic pré-implantatoire et formes héréditaires de cancers -Site des professionnels -Agence de la biomédecine, 2006.
Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer, Hum Reprod Oxf Engl. juin, vol.22, issue.6, pp.1573-1580, 2007. ,
Support needs of couples with hereditary breast and ovarian cancer during reproductive decision making, Psychooncology. juill, vol.27, issue.7, pp.1795-801, 2018. ,